SHORT-TERM operational issues assoicated with the rollout of Sigma Healthcare's Enterprise Resource Planning (ERP) and the impacts of COVID-19, have prompted the company to downgrade its earnings guidance for the financial year to 31 Jan 2022 (FY22).
In a statement to the Australian Securities Exchange (ASX) this morning the pharmaceutical wholesaler forecast that its underlying earnings before interest, tax, depreciation and amortisation will be down "around 10% versus FY21".
Sigma Interim Chief Financial Officer, Jeff Sells, said the company was confident the issues around the implementation of the ERP were "largely confined to FY22", and would abate during FY23.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Dec 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Dec 21
